S
Shmuel Odes
Researcher at Ben-Gurion University of the Negev
Publications - 51
Citations - 2335
Shmuel Odes is an academic researcher from Ben-Gurion University of the Negev. The author has contributed to research in topics: Inflammatory bowel disease & Crohn's disease. The author has an hindex of 21, co-authored 48 publications receiving 2085 citations.
Papers
More filters
Journal ArticleDOI
East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort
Johan Burisch,Niels C Pedersen,Silvija Čuković-Čavka,Marko Brinar,I. Kaimakliotis,Dana Duricova,Olga Shonová,Ida Vind,Søren Avnstrøm,Niels Thorsgaard,Vibeke Andersen,Simon Laiggard Krabbe,Jens Frederik Dahlerup,Riina Salupere,K R Nielsen,J. Olsen,Pekka Manninen,Pekka Collin,E.V. Tsianos,Konstantinos Katsanos,K. Ladefoged,Laszlo Lakatos,Einar Björnsson,G. Ragnarsson,Y. Bailey,Shmuel Odes,Doron Schwartz,Matteo Martinato,Guido Lupinacci,Monica Milla,A. De Padova,Renata D'Incà,M Beltrami,Limas Kupčinskas,Gediminas Kiudelis,Svetlana Turcan,O Tighineanu,I Mihu,Fernando Magro,Fernando Magro,L. Barros,Adrian Goldis,Daniela Lazăr,Elena Belousova,Inna Nikulina,Veronica Moset Hernandez,D. Martinez-Ares,Sven Almer,Yaroslava Zhulina,Jonas Halfvarson,Naila Arebi,Shaji Sebastian,Peter L. Lakatos,Ebbe Langholz,Pia Munkholm +54 more
TL;DR: Whether an East–West gradient in the incidence of inflammatory bowel disease in Europe exists is investigated to find out whether international guidelines for diagnosis and initial treatment are not being followed uniformly by physicians.
Journal ArticleDOI
Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial.
Ran Oren,Nadir Arber,Shmuel Odes,Menachem Moshkowitz,D. Keter,I Pomeranz,Yulia Ron,I Reisfeld,Efrat Broide,Alexandra Lavy,Alexander Fich,Rami Eliakim,J Patz,Eytan Bardan,Yael Villa,Tuvia Gilat +15 more
TL;DR: Methotrexate at a weekly oral dose of 12.5 mg was not found to be better than placebo in the induction or maintenance of remission in patients with chronic active ulcerative colitis.
Journal ArticleDOI
Budesonide versus prednisone in the treatment of active Crohn's disease
Simon Bar Meir,Yehuda Chowers,Alexandra Lavy,Dov Abramovitch,Amos Sternberg,Georges Leichtmann,Ron Reshef,Shmuel Odes,Menachem Moshkovitz,Raphael Bruck,Rami Eliakim,Eran Maoz,Ulrich Mittmann +12 more
TL;DR: BUD is as effective as PRED in the treatment of CD involving the terminal ileum and right colon and has significantly fewer steroid-related adverse reactions.
Journal ArticleDOI
Phenotype at diagnosis predicts recurrence rates in Crohn’s disease
Frank Wolters,Maurice G. Russel,Jildou Sijbrandij,T. Ambergen,Shmuel Odes,L. Riis,Ebbe Langholz,P. Politi,A. Qasim,Ioannis E. Koutroubakis,E.V. Tsianos,Severine Vermeire,Joao Freitas,G. Van Zeijl,Ole Høie,Tomm Bernklev,M Beltrami,D. Rodriguez,Reinhold W. Stockbrügger,Bjørn Moum +19 more
TL;DR: A mild course of disease in terms of disease recurrence was observed in this European cohort of Crohn’s disease patients and phenotypic traits at diagnosis had predictive value for diseaseRecurrence with upper gastrointestinal disease being the most important positive predictor.
Journal Article
Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial.
Ran Oren,Menachem Moshkowitz,Shmuel Odes,S Becker,D. Keter,I Pomeranz,Haim Shirin,I Reisfeld,Efrat Broide,Alexandra Lavy,Alexander Fich,Rami Eliakim,J Patz,Yael Villa,Nadir Arber,Tuvia Gilat +15 more
TL;DR: Methotrexate at a weekly oral dose of 12.5 mg was found to be moderately better than 6-mercaptopurine and placebo in patients with chronic active CD.